Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD38 monoclonal antibody SG301

A human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that targets the cell surface glycoprotein CD38, with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SG301 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:SG 301
SG-301
SG301
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search